Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hitoshi Takeshima is active.

Publication


Featured researches published by Hitoshi Takeshima.


Fertility and Sterility | 1986

A comparative study of seminal trace elements in fertile and infertile men

Tomokazu Umeyama; Hiromichi Ishikawa; Hitoshi Takeshima; Shinichi Yoshii; Kenkichi Koiso

Fourteen kinds of trace elements were analyzed in the semen of 22 fertile men and 69 infertile men by means of inductively coupled plasma optical emission spectroscopy. Ca had the highest concentration, and the second and third highest concentrations were Zn and Mg, respectively. The concentrations of Ca, Cr, Mg, Pb, Sr, and Zn were almost the same between fertile and infertile men. Ni had a lower concentration in infertile than in fertile men. Many trace elements, such as Al, Cd, Cu, Mg, Mn, Mo, Sn, and Zn, had significantly higher concentrations in infertile men with normozoospermia than in fertile men. There was a significantly positive correlation between Zn and Mg levels in fertile and infertile men.


International Journal of Urology | 2002

Clinical study of varicocele: statistical analysis and the results of long-term follow-up.

Mizuki Onozawa; Fumiyasu Endo; Takahiro Suetomi; Hitoshi Takeshima; Hideyuki Akaza

Background: The results of clinical examinations of varicocele and the clinical outcome of varicocelectomy conducted at Tsukuba University Hospital, Tsukuba City, Japan were analyzed.


International Journal of Urology | 2004

Intraoperative transesophageal echocardiography for inferior vena caval tumor thrombus in renal cell carcinoma

Takehiro Oikawa; Toru Shimazui; Akira Johraku; Shinichi Kihara; Sadamu Tsukamoto; Naoto Miyanaga; Kazunori Hattori; Koji Kawai; Katsunori Uchida; Hitoshi Takeshima; Shigeyuki Saito; Hidenori Toyooka; Hideyuki Akaza

Background : We investigated the advantages of intraoperative transesophageal echocardiography (TEE) during inferior vena caval tumor thrombectomy in renal cell carcinoma (RCC).


International Journal of Urology | 2000

A bladder preservation regimen using intra‐arterial chemotherapy and radiotherapy for invasive bladder cancer: A prospective study

Naoto Miyanaga; Hideyuki Akaza; Toshiyuki Okumura; Noritoshi Sekido; Koji Kawai; Toru Shimazui; Koji Kikuchi; Katsunori Uchida; Hitoshi Takeshima; Kiyoshi Ohara; Yasuyuki Akine; Yuji Itai

Background : A prospective study was performed to investigate combined treatment with intra‐arterial chemotherapy and radiation therapy for bladder preservation in locally invasive bladder cancer.


International Journal of Urology | 2003

Protecting spermatogonia from apoptosis induced by doxorubicin using the luteinizing hormone-releasing hormone analog leuprorelin

Fumiyasu Endo; Fumio Manabe; Hitoshi Takeshima; Hideyuki Akaza

Abstract Purpose: The present study was performed to investigate the protective effect of leuprorelin (LH‐RH analog), on spermatogonia apoptosis induced by doxorubicin (DXR) in the Sprague–Dawley rat model.


The Journal of Urology | 1982

Renal Autotransplantation for Localized Amyloidosis of the Ureter

Tsunetada Yazaki; Tatsuo Iizumi; Yoshihide Ogawa; Hitoshi Takeshima; Tomokazu Umeyama; Ryosuke Nemoto; Kenji Rinsho; Shigeki Takahashi; Shori Kanoh; Ryuichi Kitagawa

Localized amyloidosis of the ureter is a relatively rare disease, causing at times ureteral stenosis with hydronephrosis and renal function impairment to various extent. Although it is not malignant nearly all reported cases have been treated by nephroureterectomy because it is clinically difficult to differentiate this entity from ureteral malignancy. We report a case in which the ipsilateral kidney was salvaged successfully by renal autotransplantation. To the best of our knowledge, this is the first case reported of renal autotransplantation for localized amyloidosis of the ureter in the English literature. We suggest that renal autotransplantation be considered in cases of localized ureteral amyloidosis.


Cancer | 1997

Protecting spermatogenesis from damage induced by doxorubicin using the luteinizing hormone-releasing hormone agonist leuprorelin

Fumio Manabe; Hitoshi Takeshima; Hideyuki Akaza

This study was performed to investigate the protective effect of a luteinizing hormone‐releasing hormone (LHRH) agonist, leuprorelin, against spermatogenetic damage caused by doxorubicin in rats.


International Journal of Urology | 2000

High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer

Jun Miyazaki; Naoto Miyanaga; Koji Kawai; Toru Shimazui; Hitoshi Takeshima; Hideyuki Akaza

Background : The present study was performed in order to investigate the efficacy and safety of high‐dose chemotherapy for the treatment of patients with advanced testicular cancer.


International Journal of Urology | 1996

Adrenal Myelolipoma Associated with Hereditary Spherocytosis

Noritoshi Sekido; Koji Kawai; Hitoshi Takeshima; Katsunori Uchida; Hideyuki Akaza; Kenkichi Koiso

Myelolipomas are benign tumors composed of mature fat and bone marrow elements. We report a case of adrenal myelolipoma associated with hereditary spherocytosis which was treated with splenectomy seventeen years ago. The hematopoietic stimulus of the hereditary spherocytosis might have been associated with the development of adrenal myelolipoma in the present case.


Urologia Internationalis | 1995

The Importance of Dose Intensity in Chemotherapy of Advanced Testicular Cancer

Naoto Miyanaga; Hideyuki Akaza; Kazunori Hattori; Hitoshi Takeshima; Kenkichi Koiso

PVB regimen, the combination of cisplatin (CDDP), vinblastine (VLB) and bleomycin (BLM), has improved the treatment results of testicular cancer patients. However, modification of doses and schedules were strongly related with the treatment results. We analyzed the relative dose intensity (RDI) of each patient undergoing PVB regimen, in relation to the chemotherapeutic effect. In addition, a role of granulocyte colony-stimulating factor (G-CSF) on dose intensity of PVB regimen was analyzed. During the period 1981-1992, 33 patients with testicular cancer were treated with PVB regimen. Among the 25 evaluable patients, 5 (20%) achieved a complete response (CR), 15 (60%) had a partial response (PR), and the overall response rate was 80%. The average 5-year survival rate of all cases was 78.4%. The RDI in CR and PR cases were significantly higher than nonresponders in BLM (0.89 for CR and 0.91 for PR against 0.32 for NC + PD) in the combination of the three drugs (1.05 for CR and 0.97 for PR against 0.69 for NC + PD). The standard-dose group (RDI > or = 0.9) had a higher survival rate than the modified-dose group (RDI < 0.9). The RDI of PVB regimen with administration of G-CSF was 0.98, whereas in the PVB-alone group it was 0.87 (p < 0.01). Our findings indicate that the RDI of BLM may be one of the most important factors in achieving a chemotherapeutic effect from the PVB regimen. G-CSF is useful for the completion of the schedule through the increase in dose intensification, and the prevention of leukocytopenia due to chemotherapy.

Collaboration


Dive into the Hitoshi Takeshima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge